Nivolumab: beside a new treatment under test
581 studies: a new drug, cell therapy or vaccine is what the study tests. Page 4 of 6. Open to participants first (106), then studies with results posted, then the rest; newest registration first within each.
- A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic CancerActive, not recruitingNCT06532331Phase 1How we knowReport a problem
- Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)WithdrawnNCT06400264Phase 2How we knowReport a problem
- A Study to Test the Benefit of Vitamin B5 in Patients With MelanomaActive, not recruitingNCT06377111Phase 1How we knowReport a problem
- Trial of INI-4001 in Patients With Advanced Solid TumoursCompletedNCT06302426Phase 1How we knowReport a problem
- A Study of BND-35 in Participants With Advanced Solid TumorsTerminatedNCT06274437Phase 1How we knowReport a problem
- A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)Active, not recruitingNCT06256328Phase 2How we knowReport a problem
- Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)TerminatedNCT06191796Phase 1How we knowReport a problem
- Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder CancerCompletedNCT06059547Phase 2How we knowReport a problem
- Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell CarcinomaSuspendedNCT06049576Phase 1How we knowReport a problem
- Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer TypesTerminatedNCT06034860Phase 1How we knowReport a problem
- Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung CancerActive, not recruitingNCT06015724Phase 2How we knowReport a problem
- Study of LP-184 in Patients With Advanced Solid TumorsActive, not recruitingNCT05933265Phase 1/2How we knowReport a problem
- A Study of IO102/IO103, Nivolumab, and Relatlimab in People With MelanomaActive, not recruitingNCT05912244Phase 2How we knowReport a problem
- Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal CancerWithdrawnNCT05898828Phase 1/2How we knowReport a problem
- A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid TumorsActive, not recruitingNCT05888831Phase 1/2How we knowReport a problem
- A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010CompletedNCT05867121Phase 1How we knowReport a problem
- Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.Active, not recruitingNCT05788081Phase 2How we knowReport a problem
- Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHNWithdrawnNCT05743270Phase 2How we knowReport a problem
- Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin LymphomaActive, not recruitingNCT05723055Phase 2How we knowReport a problem
- Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic CancerCompletedNCT05721846Phase 1How we knowReport a problem
- Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the LungWithdrawnNCT05717140Phase 1How we knowReport a problem
- Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ TumorsActive, not recruitingNCT05704985Phase 1How we knowReport a problem
- Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell CarcinomaActive, not recruitingNCT05678673Phase 3How we knowReport a problem
- A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid TumorsCompletedNCT05625412Phase 1How we knowReport a problem
- ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)TerminatedNCT05601752Phase 2How we knowReport a problem
- Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLCTerminatedNCT05583188Phase 4How we knowReport a problem
- A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor MalignancyTerminatedNCT05581719Phase 1/2How we knowReport a problem
- Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.Active, not recruitingNCT05501054Phase 1/2How we knowReport a problem
- Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck CancerWithdrawnNCT05472506Phase 1How we knowReport a problem
- F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung CancerStatus unknownNCT05468294Phase 1/2How we knowReport a problem
- Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutantWithdrawnNCT05457959Phase 1How we knowReport a problem
- Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate CancerSuspendedNCT05445609Phase 2How we knowReport a problem
- FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid TumorsTerminatedNCT05395052Phase 1How we knowReport a problem
- SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS MutationTerminatedNCT05375084Phase 1How we knowReport a problem
- A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128Active, not recruitingNCT05354102Phase 1How we knowReport a problem
- Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline TherapyActive, not recruitingNCT05352828Phase 1How we knowReport a problem
- Efficacy of VTP-300 in Chronic Hepatitis B InfectionCompletedNCT05343481Phase 2How we knowReport a problem
- A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.TerminatedNCT05322577Phase 1/2How we knowReport a problem
- Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and MelanomaCompletedNCT05303493Phase 1How we knowReport a problem
- A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced TumorsCompletedNCT05298592Phase 1How we knowReport a problem
- A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma PatientsStatus unknownNCT05281926Phase 1How we knowReport a problem
- HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination TherapyActive, not recruitingNCT05280457Phase 2How we knowReport a problem
- Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLCStatus unknownNCT05265650Phase 1/2How we knowReport a problem
- NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine CarcinomasCompletedNCT05262556Phase 1How we knowReport a problem
- Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney CancerActive, not recruitingNCT05239533Phase 2How we knowReport a problem
- A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLCStatus unknownNCT05236608Phase 1/2How we knowReport a problem
- A Study of Oncolytic Virus Injection (RT-01) in Combination With PD-1 Inhibitor in Patients With Advanced Solid TumorsStatus unknownNCT05228119Phase 1How we knowReport a problem
- Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver TumorsTerminatedNCT05220722Phase 1/2How we knowReport a problem
- Personalized DC Vaccines in Non Small Cell Lung CancerActive, not recruitingNCT05195619Phase 1How we knowReport a problem
- A Phase 1/2 Study of BA3071 in Patients With Solid TumorsActive, not recruitingNCT05180799Phase 1/2How we knowReport a problem
- GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular CarcinomaActive, not recruitingNCT05178043Phase 2How we knowReport a problem
- Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 ExpressionActive, not recruitingNCT05163041Phase 1/2How we knowReport a problem
- Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract CancersWithdrawnNCT05153304Phase 1/2How we knowReport a problem
- RT-01 Monotherapy and in Combination With Nivolumab in Patients With Advanced Solid TumorsStatus unknownNCT05122572Phase 1How we knowReport a problem
- CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney CancerActive, not recruitingNCT05122546Phase 1How we knowReport a problem
- Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Phase 3How we knowReport a problem
- A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid TumorsCompletedNCT05108623Phase 1How we knowReport a problem
- FT538 in Combination With Monoclonal Antibodies in Advanced Solid TumorsTerminatedNCT05069935Phase 1How we knowReport a problem
- Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial TumoursCompletedNCT05043714Phase 1How we knowReport a problem
- A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN)Status unknownNCT05027204Phase 1/2How we knowReport a problem
- Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME StudyWithdrawnNCT05022394Phase 1/2How we knowReport a problem
- Gut Microbiota Reconstruction for NSCLC ImmunotherapyStatus unknownNCT05008861Phase 1How we knowReport a problem
- Study of FMT Combined With Nivolumab in Gastric CancerWithdrawnNCT05001360Not applicableHow we knowReport a problem
- Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate CancerActive, not recruitingNCT04989946Phase 1/2How we knowReport a problem
- Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOmaCompletedNCT04988841Phase 2How we knowReport a problem
- Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver CancerWithdrawnNCT04965714Phase 2How we knowReport a problem
- A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and NivolumabWithdrawnNCT04955262Phase 1How we knowReport a problem
- Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic CancerCompletedNCT04953962Phase 2How we knowReport a problem
- ARID1A and/or KDM6A Mutation and CXCL13 ExpressionActive, not recruitingNCT04953104Phase 2How we knowReport a problem
- Fecal Microbial Transplantation Non-Small Cell Lung Cancer and MelanomaActive, not recruitingNCT04951583Phase 2How we knowReport a problem
- A Study of BMS-986416 With and Without Nivolumab in Select Solid TumorsCompletedNCT04943900Phase 1How we knowReport a problem
- Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal MelanomaTerminatedNCT04935229Phase 1How we knowReport a problem
- NeoVax + CDX-301 and Nivolumab or Pembrolizumab in MelanomaActive, not recruitingNCT04930783Phase 1How we knowReport a problem
- Study of XB002 in Subjects With Solid Tumors (JEWEL-101)CompletedNCT04925284Phase 1How we knowReport a problem
- Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell CancerTerminatedNCT04904302Phase 2How we knowReport a problem
- Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid TumorsTerminatedNCT04892043Phase 1How we knowReport a problem
- PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of SubstratesCompletedNCT04887194Phase 1How we knowReport a problem
- Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)Active, not recruitingNCT04884282Phase 2How we knowReport a problem
- Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck CaActive, not recruitingNCT04848116Phase 2How we knowReport a problem
- Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid TumorsSuspendedNCT04840589Phase 1How we knowReport a problem
- A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.Active, not recruitingNCT04835805Phase 1How we knowReport a problem
- Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid MalignanciesTerminatedNCT04785287Phase 1/2How we knowReport a problem
- FL-101 in Surgically Resectable Non-Small Cell Lung CancerWithdrawnNCT04758949Phase 2How we knowReport a problem
- Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid TumoursActive, not recruitingNCT04735978Phase 1How we knowReport a problem
- A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid TumorsCompletedNCT04731467Phase 1/2How we knowReport a problem
- Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-respondersActive, not recruitingNCT04729322Phase 2How we knowReport a problem
- First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)Active, not recruitingNCT04725474Phase 1/2How we knowReport a problem
- Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced MelanomaActive, not recruitingNCT04674683Phase 3How we knowReport a problem
- The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D InfectionCompletedNCT04638439Phase 1How we knowReport a problem
- Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic CancerActive, not recruitingNCT04627246Phase 1How we knowReport a problem
- Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal OriginStatus unknownNCT04620954Phase 1/2How we knowReport a problem
- PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic CancerStatus unknownNCT04612530Phase 1How we knowReport a problem
- Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBCCompletedNCT04610671Phase 1How we knowReport a problem
- SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 TrialActive, not recruitingNCT04599140Phase 1/2How we knowReport a problem
- NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal AdenocarcinomaTerminatedNCT04594811Phase 1How we knowReport a problem
- Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and MelanomaActive, not recruitingNCT04572451Phase 1How we knowReport a problem
- COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.CompletedNCT04570839Phase 1/2How we knowReport a problem
- A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has SpreadCompletedNCT04540705Phase 1How we knowReport a problem
- A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLCStatus unknownNCT04521075Phase 1/2How we knowReport a problem
- Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid MalignanciesCompletedNCT04518046Phase 1How we knowReport a problem